AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
-0.14 (-0.41%)
Jul 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 33.47 - 34.33
52 week 26.97 - 34.88
Open 34.01
Vol / Avg. 11.51M/7.35M
Mkt cap 90.97B
P/E 29.57
Div/yield 0.95/4.10
EPS 1.15
Shares 1.26B
Beta 0.74
Inst. own 22%
Aug 1, 2016
AstraZeneca PLC Investor Roadshow - London, Edinburgh, Europe and North America Add to calendar
Jul 28, 2016
Q2 2016 AstraZeneca PLC Earnings Call - Webcast
Jul 28, 2016
Q2 2016 AstraZeneca PLC Earnings Release
Jul 6, 2016
AstraZeneca PLC IR Roadshow - Munich
Jul 5, 2016
AstraZeneca PLC IR Roadshow - Cologne, Stuttgart
Jun 21, 2016
AstraZeneca PLC at Citi European Healthcare Conference
Jun 8, 2016
AstraZeneca PLC at Jefferies Healthcare Conference
Jun 6, 2016
AstraZeneca PLC Investor Science Event at ASCO 2016 - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 10.22% 11.44%
Operating margin 16.97% 16.65%
EBITD margin - 32.20%
Return on average assets 4.03% 4.76%
Return on average equity 15.59% 14.82%
Employees 61,500 -
CDP Score - 97 B


- Legal Department, 2 Kingdom Street
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Bio & Compensation  - Reuters
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Bio & Compensation  - Reuters
Fiona Cicconi Executive Vice-President, Human Resources
Bio & Compensation  - Reuters
Sean Bohen M.D. Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Luke Miels Executive Vice-President, GPPS
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters